RT Journal Article
SR Electronic
T1 Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.19.21260802
DO 10.1101/2021.07.19.21260802
A1 Matt D.T. Hitchings
A1 Otavio T. Ranzani
A1 Murilo Dorion
A1 Tatiana Lang D’Agostini
A1 Regiane Cardoso de Paula
A1 Olivia Ferreira Pereira de Paula
A1 Edlaine Faria de Moura Villela
A1 Mario Sergio Scaramuzzini Torres
A1 Silvano Barbosa de Oliveira
A1 Wade Schulz
A1 Maria Almiron
A1 Rodrigo Said
A1 Roberto Dias de Oliveira
A1 Patricia Vieira da Silva
A1 Wildo Navegantes de Araújo
A1 Jean Carlo Gorinchteyn
A1 Jason R. Andrews
A1 Derek A.T. Cummings
A1 Albert I. Ko
A1 Julio Croda
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260802.abstract
AB Background A two-dose regimen of ChAdOx1 coronavirus disease 19 (Covid-19) vaccine with an inter-dose interval of three months has been implemented in many countries with restricted vaccine supply. However, there is limited evidence for the effectiveness of ChAdOx1 by dose in elderly populations in countries with high prevalence of the Gamma variant of severe acute respiratory syndrome 2 (SARS-CoV-2).Methods We conducted a test-negative case-control study to estimate the effectiveness of ChAdOx1 vaccine in adults aged 60 years or older during a Gamma-variant-associated epidemic in São Paulo state, Brazil, between 17 January and 2 July 2021. Cases and matched test-negative controls were individuals, identified from surveillance databases, who experienced an acute respiratory illness and underwent SARS-CoV-2 RT-PCR testing. We used conditional logistic regression to estimate the effectiveness by dose against RT-PCR-confirmed Covid-19, Covid-19 hospitalization, and Covid-19-related death.Results 61,164 individuals were selected into matched case-control pairs. Starting ≥28 days after the first dose, adjusted effectiveness of a single dose of ChAdOx1 was 33.4% (95% CI, 26.4 to 39.7) against Covid-19, 55.1% (95% CI, 46.6 to 62.2) against hospitalization, and 61.8% (95% CI, 48.9 to 71.4) against death. Starting ≥14 days after the second dose, the adjusted effectiveness of the two-dose schedule was 77.9% (95% CI, 69.2 to 84.2) against Covid-19, 87.6% (95% CI, 78.2 to 92.9) against hospitalization, and 93.6% (95% CI, 81.9 to 97.7) against death.Conclusions Completion of the ChAdOx1 vaccine schedule afforded significantly increased protection over a single dose against mild and severe Covid-19 outcomes in elderly individuals during widespread Gamma variant transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful for the Pan American Health Organization's support and the São Paulo State in making the databases available for analysis. JC is supported by the Oswaldo Cruz Foundation (Edital Covid-19 - resposta rápida: 48111668950485). OTR is funded by a Sara Borrell fellowship (CD19/00110) from the Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program and from the Generalitat de Catalunya through the CERCA Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee for Research of Federal University of Mato Grosso do Sul (CAAE: 43289221.5.0000.0021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified databases as well as the R codes will be deposited in the repository https://github.com/juliocroda/VebraCOVID-19 https://github.com/juliocroda/VebraCOVID-19